NASDAQ false 0001183765 0001183765 2024-09-27 2024-09-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 27, 2024

 

 

Molecular Templates, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32979   94-3409596
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

9301 Amberglen Blvd, Suite 100
Austin, Texas 78729
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (512) 869-1555

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   MTEM   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On September 27, 2024, Molecular Templates, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a quorum of 4,676,739 shares of the Company’s common stock, or 71.03% of the outstanding shares of common stock entitled to vote as of the record date of August 1, 2024, were present in person or represented by proxy. At the Annual Meeting, the stockholders: (1) elected Corsee Sanders, Ph.D. to the Company’s Board of Directors as a Class II director for a term of three years to serve until the 2027 annual meeting of stockholders and until her successor is elected and qualified or until her earlier death, resignation or removal (“Election of Director”); (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Auditor Ratification”); and (3) approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the meeting (“Advisory Vote on Executive Compensation”). A more complete description of each of these matters is set forth in the Company’s proxy statement.

The number of votes cast in favor or against by the stockholders and the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

 

1.

Election of Director

 

Nominee  

Shares

Voted For

  

Shares

Voted

Against

  

Shares

Abstaining

  

Broker

Non-votes

Corsee Sanders, Ph.D.

   3,031,323   553,546   139   1,091,731

 

2.

Auditor Ratification

 

Shares

Voted For

  

Shares

Voted

Against

  

Shares

Abstaining

4,639,921

  

28,744

  

8,074

 

3.

Advisory Vote on Executive Compensation

 

Shares

Voted For

  

Shares

Voted

Against

  

Shares

Abstaining

  

Broker

Non-votes

3,561,675

   22,865   468   1,091,731

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Molecular Templates, Inc.
Dated: September 27, 2024      
    By:  

/s/ Eric E. Poma, Ph.D.

      Name: Eric E. Poma, Ph.D.
      Title: Chief Executive Officer

 

3

v3.24.3
Document and Entity Information
Sep. 27, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001183765
Document Type 8-K
Document Period End Date Sep. 27, 2024
Entity Registrant Name Molecular Templates, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-32979
Entity Tax Identification Number 94-3409596
Entity Address, Address Line One 9301 Amberglen Blvd
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78729
City Area Code (512)
Local Phone Number 869-1555
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol MTEM
Entity Emerging Growth Company false
Grafico Azioni Molecular Templates (NASDAQ:MTEM)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Molecular Templates
Grafico Azioni Molecular Templates (NASDAQ:MTEM)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Molecular Templates